Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

Our prognostic model, including five clinical factors, is useful for patient care and treatment selection in high-risk mHSPC patients treated with ADT plus ABI. The developed model could provide more accurate information, guide treatment decisions, or classify patients in future clinical trials.

Authors

Institutions

Publication Details

Journal
The Prostate
Published
2024-09-30
DOI
https://doi.org/10.1002/pros.24802
Citations
2
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.84

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

Kenichi Hata, Osamu Ukimura, Shingo Hatakeyama, Tomonori Habuchi et al.
2 citations
The Prostate
Prostate Cancer Treatment and Research
0.84
article

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

Kenichi Hata, Osamu Ukimura, Shingo Hatakeyama, Tomonori Habuchi, Mizuki Kobayashi, Ikuya Iwabuchi, Kazuyuki Numakura, Takashi Ueda, Yohei Horikawa, Takafumi Yanagisawa, Jiro Shimoda, Shintaro Narita, Soki Kashima, Ryohei Yamamoto, Katsumi Okane, Takehiro Suzuki, Yuya Sekine, Kazutoshi Fujita, Mitsuru Saito, Toshikazu Tanaka, Chikara Οhyama, K. Takayama, Takahiro Kimura, Teruaki Kumazawa, Hiromi Sato, Shinya Maita, Toshiya Ishida, Shuji Chiba, Kyoko Nomura
article en
2 citations

Abstract

Our prognostic model, including five clinical factors, is useful for patient care and treatment selection in high-risk mHSPC patients treated with ADT plus ABI. The developed model could provide more accurate information, guide treatment decisions, or classify patients in future clinical trials.

The ProstateVol. 85(1)
Jikei University School of Medicine (JP), Hirosaki University (JP), Akita University (JP), Kyoto Prefectural University of Medicine (JP), Aomori Prefectural Central Hospital (JP), Iwate Prefectural Central Hospital (JP), Akita University Hospital (JP), Akita Red Cross Hospital (JP), Yokosuka Kyosai Hospital (JP), Kumiai Chemical Industry (Japan) (JP), Hiraka General Hospital (JP), Kindai University (JP)
Japan Society for the Promotion of Science
No poverty
Openalex Percentile: Top 24%
Prostate Cancer Treatment and Research
0.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.